Cargando…

Apoptotic mitochondria prime anti-tumour immunity

Detalles Bibliográficos
Autores principales:	McArthur, Kate, Kile, Benjamin T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542170/ https://www.ncbi.nlm.nih.gov/pubmed/33083019 http://dx.doi.org/10.1038/s41420-020-00335-6

Ejemplares similares

Remote tissue immune priming in allergic disease
por: Ubags, Niki D.
Publicado: (2020)

The antiproliferative and apoptotic profile of gomesin against DFTD
por: Ikonomopoulou, Maria P., et al.
Publicado: (2018)

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
por: Feldmann, Marc, et al.
Publicado: (2020)

Glucocerebrosidase mutations disrupt the lysosome and now the mitochondria
por: Klein, Andrés D., et al.
Publicado: (2023)

Bax Exists in a Dynamic Equilibrium between the Cytosol and Mitochondria to Control Apoptotic Priming
por: Schellenberg, Barbara, et al.
Publicado: (2013)

Apoptotic priming is defined by the dynamic exchange of Bcl-2 proteins between mitochondria and cytosol
por: King, Louise E., et al.
Publicado: (2022)

Cell death following the loss of ADAR1 mediated A-to-I RNA editing is not effected by the intrinsic apoptosis pathway
por: Walkley, Carl R., et al.
Publicado: (2019)

Calcium mobilization from mitochondria in synaptic transmitter release
por: Rizzuto, Rosario
Publicado: (2003)

Awake prone positioning in COVID-19: is tummy time ready for prime time?
por: Weatherald, Jason, et al.
Publicado: (2021)

Organellar stress intersects the astrocyte endoplasmic reticulum, mitochondria and nucleolus in HIV associated neurodegeneration
por: Nooka, Shruthi, et al.
Publicado: (2018)

Tumour-agnostic drugs in paediatric cancers
por: Chisholm, Julia C., et al.
Publicado: (2020)

Novel insights into the role of anti-inflammatory IL-38 in immunity against infection
por: Gao, Xun, et al.
Publicado: (2022)

Proteasome inhibition—a new target for brain tumours
por: Rashid, Fatima, et al.
Publicado: (2019)

BTK: a two-faced effector in cancer and tumour suppression
por: Rada, Miran, et al.
Publicado: (2018)

Precision radiogenomics: fusion biopsies to target tumour habitats in vivo
por: Crispin-Ortuzar, Mireia, et al.
Publicado: (2021)

Population immunity and vaccine protection against infection
por: Leshem, Eyal, et al.
Publicado: (2021)

Primary hyperoxaluria type 1: time for prime time?
por: Bacchetta, Justine, et al.
Publicado: (2022)

Mitochondria Released by Apoptotic Cell Death Initiate Innate Immune Responses
por: Zhu, Minghua, et al.
Publicado: (2018)

Mitochondria Released by Apoptotic Cell Death Initiate Innate Immune Responses
por: Zhu, Minghua, et al.
Publicado: (2019)

T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
por: Hanley, Christopher J., et al.
Publicado: (2020)

IL-10-Mediated Refueling of Exhausted T Cell Mitochondria Boosts Anti-Tumour Immunity
por: Ryan, Dylan, et al.
Publicado: (2021)

Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases
por: Goulenok, Tiphaine, et al.
Publicado: (2022)

National brain tumour registry: a new era of research collaboration with China
por: Valvi, Santosh, et al.
Publicado: (2023)

Apoptotic mitochondria blow a fuse
por: Dove, Alan W.
Publicado: (2004)

A Mitochondria-Initiated Apoptotic Pathway
por: Wang, Xiaodong
Publicado: (2001)

Tyrosine kinase inhibitor-induced hypertension—marker of anti-tumour treatment efficacy or cardiovascular risk factor?
por: Ptinopoulou, Anastasia G., et al.
Publicado: (2020)

Prime time for base editing in the mitochondria
por: Morgan, Michael A., et al.
Publicado: (2022)

Speaking up for the lost voices: representation and inclusion of people with communication impairment in brain tumour research
por: Menger, Fiona, et al.
Publicado: (2023)

Evolutionary considerations on the origin of peroxisomes from the endoplasmic reticulum, and their relationships with mitochondria
por: Gabaldón, Toni
Publicado: (2014)

cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity
por: Ferris, Stephen T., et al.
Publicado: (2020)

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination
por: Anderson, Roy M, et al.
Publicado: (2020)

Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination
por: Pasqualetti, Francesco, et al.
Publicado: (2023)

Targeting Tumor Stroma: Exploiting Apoptotic Priming
por: Mertens, Joachim C., et al.
Publicado: (2012)

COVID-19 vaccination in patients with immunity-mediated kidney disease
por: Prendecki, Maria, et al.
Publicado: (2021)

Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells
por: Tan, Grace Min Yi, et al.
Publicado: (2022)

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
por: Oosting, Sjoukje F, et al.
Publicado: (2022)

Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy
por: Bodmer, Walter
Publicado: (2022)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

COVID-19 and the anti-lessons of history
por: Peckham, Robert
Publicado: (2020)

SARS-CoV-2: from herd immunity to hybrid immunity
por: Goldblatt, David
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_il1lsqok4fdop5ak30dqa7d0hh